Sulindac

Nonsteroidal Anti-inflammatory Drug — MUSCULO-SKELETAL SYSTEM

Key facts

Sulindac is an ofp drug in the Nonsteroidal Anti-inflammatory Drug class catalogued in DrugCentral. It was first approved by the FDA in 1978. Its mechanism of action is classified as Cyclooxygenase Inhibitors. DrugCentral lists 14 molecular targets, including AKR1B10, AKR1B1 and GLRA1. Recorded indications include Ankylosing spondylitis, Articular gout, Bursitis and Osteoarthritis.

• Approval status: ofp (first approved 1978 by the FDA).
• Drug class: Nonsteroidal Anti-inflammatory Drug.
• Mechanism of action: Cyclooxygenase Inhibitors.
• Molecular targets: AKR1B10, AKR1B1, GLRA1 and Akr1b1 (14 listed in DrugCentral).
• Indications: Ankylosing spondylitis, Articular gout, Bursitis, Osteoarthritis and Rheumatoid arthritis and others.
• ATC code: M01AB02 (Acetic acid derivatives and related substances).
• Molecular formula: C20H17FO3S; molecular weight 356.41 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (6)

• Ankylosing spondylitis
• Articular gout
• Bursitis
• Osteoarthritis
• Rheumatoid arthritis
• Tendinitis

Contraindications (23)

• Alcoholism
• Anemia
• Asthenia
• Blood coagulation disorder
• Breastfeeding (mother)
• Cardiovascular event risk
• Chronic heart failure
• Coronary artery bypass graft
• Disease of liver
• Disorder of cardiovascular system
• Disorder of connective tissue
• Edema
• Gastrointestinal hemorrhage
• Gastrointestinal perforation
• Gastrointestinal ulcer
• Hypertensive disorder
• Kidney disease
• Kidney stone
• Myocardial infarction
• Peptic ulcer
• Pregnancy, function
• Smokes tobacco daily
• Systemic lupus erythematosus

Mechanism & targets

• Mechanism of action (MoA): Cyclooxygenase Inhibitors
• Established pharmacologic class: Nonsteroidal Anti-inflammatory Drug

Molecular targets (14)

Target	Gene	Action	Activity
Aldo-keto reductase family 1 member B10	AKR1B10	unknown	IC50 6.46
Aldose reductase	AKR1B1	unknown	IC50 6.43
Glycine receptor subunit alpha-1	GLRA1	unknown	EC50 6.42
Aldose reductase	Akr1b1	unknown	IC50 6.36
Complement C5	C5	unknown	Kd 6.24
Prostaglandin G/H synthase 1	PTGS1	inhibitor	IC50 5.92
Prostaglandin G/H synthase 1	PTGS1	unknown	IC50 4.80
Peroxisome proliferator-activated receptor gamma	PPARG	unknown	EC50 4.64
Prostaglandin G/H synthase 2	PTGS2	inhibitor	IC50 4.25
Lactoylglutathione lyase	GLO1	unknown	Ki 4.11
Prostaglandin E synthase	PTGES	unknown	IC50 4.10
Retinoic acid receptor RXR-alpha	RXRA	unknown	IC50 4.08
Bile salt export pump	Abcb11	unknown	IC50 4.06
72 kDa type IV collagenase	MMP2	unknown	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1978-09-27	FDA	—	MERCK

ATC classification

ATC code	Therapeutic hierarchy
M01AB02	MUSCULO-SKELETAL SYSTEM › ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS › ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS › Acetic acid derivatives and related substances

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Drug hypersensitivity	112.7
Hangover	68.5
Musculoskeletal discomfort	49.8
Musculoskeletal chest pain	41.0
Skin disorder	31.9
Inflammatory pain	30.7
Neck pain	27.7
Nodal osteoarthritis	27.6
Crystal nephropathy	26.0
Accidental exposure to product	25.1
Gastric haemorrhage	24.7
Dry gangrene	23.6

Chemical structure

• Molecular formula: C₂₀H₁₇FO₃S
• Molecular weight: 356.41 g/mol
• CAS number: 38194-50-2
• InChIKey: MLKXDPUZXIRXEP-MFOYZWKCSA-N
• PubChem CID: 1548887

CC1=C(CC(O)=O)C2=C(C=CC(F)=C2)\C1=C/C1=CC=C(C=C1)S(C)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Sulindac used for?

DrugCentral lists the following indications for Sulindac: Ankylosing spondylitis, Articular gout, Bursitis, Osteoarthritis, Rheumatoid arthritis and Tendinitis.

How does Sulindac work?

Sulindac is classified as Cyclooxygenase Inhibitors; its molecular targets in DrugCentral include AKR1B10, AKR1B1, GLRA1 and Akr1b1.

When was Sulindac first approved?

Sulindac was first approved by the FDA in 1978.

What drug class does Sulindac belong to?

Sulindac is in the Nonsteroidal Anti-inflammatory Drug class.

What is the chemical formula of Sulindac?

Sulindac has the molecular formula C20H17FO3S and a molecular weight of 356.41 g/mol.

Sources

• DrugCentral drug card 2534 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL15770 — compound record and bioactivity
• PubChem CID 1548887 — chemical identifiers
• DrugBank DB00605 — drug record
• FDA UNII 184SNS8VUH — substance identity
• DailyMed: FDA labels for Sulindac — current prescribing information (label search)
• UniProt O60218 (AKR1B10) — target protein
• UniProt P15121 (AKR1B1) — target protein
• UniProt P23415 (GLRA1) — target protein
• UniProt P01031 (C5) — target protein
• UniProt P23219 (PTGS1) — target protein
• UniProt P37231 (PPARG) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.